– UK, London – Ergomed plc (LSE:ERGO), announces that Rolf Stahel, who has served as Chairman since April 2014, has indicated that he will retire from the Board at the expiry of his three year term of office on 31 March 2017. He will be succeeded by Peter George, who has been a non-executive director of the Company since July 2014. Mr. George assumes the role of Chairman Designate with immediate effect. The Company intends to appoint a further non-executive director to the Board in due course.
Dr. Miroslav Reljanović, CEO, said: “I should like to thank Rolf for his invaluable insights and experience over the last few years which have helped shape Ergomed, both through the IPO and subsequently. We appreciate the advance notice of his intention to retire from the Board as it allows for an orderly succession. With that in mind, we are fortunate to have on the Board a suitable successor in Peter, who I have enjoyed working with and I look forward to the value he can add in the years ahead.”
Mr Rolf Stahel said: “I have enjoyed my time pre and post IPO at Ergomed. I congratulate Peter George on his well merited appointment as Chairman Designate. Peter will be taking over this new responsibility for a company that continues to show strong financial performance and I am looking forward to the future of Ergomed with confidence.”
About Ergomed
Ergomed plc is a profitable UK-based business providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 50 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 100 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development. Lastly, Ergomed recently acquired a pipeline of proprietary development products for haemostasis in surgical settings.
For more information : http://www.ergomedplc.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
